Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma (confirmed by lab testing) that has gotten worse during or within 60 days of finishing their last treatment, and who have received between 1 and 3 previous treatment regimens, including at least one that contained the drug lenalidomide.
• People whose myeloma can be measured through specific blood, urine, or protein tests taken within 4 weeks of enrolling (in some cases, people without fully measurable disease may still be considered, at the lead doctor's discretion).
• People who previously received a CD38-targeted therapy (such as daratumumab), as long as their best response to that treatment was at least a partial response, they did not progress during or within 60 days of finishing it, and they did not have to stop it due to side effects.
• People who previously received the drug carfilzomib, as long as their best response was at least a partial response, they did not progress during or within 60 days of finishing it, and they did not have to stop it due to side effects.
• People whose kidneys are functioning well enough, based on a kidney function test taken within 4 weeks of enrolling.
• People aged 18 to 75 years at the time of signing the consent form.
• People who are generally able to carry out daily activities, rated as reasonably functional on a standard medical performance scale (score of 0–2), assessed within 4 weeks of enrolling.
• People with adequate blood counts (white blood cells, red blood cells, and platelets) within 4 weeks of enrolling, though blood transfusions or growth factor support are allowed to help meet these levels.
• People with adequate liver function, based on blood tests taken within 4 weeks of enrolling.
• People who are able to take blood-thinning medication to reduce the risk of blood clots (such as a specific type of oral tablet or an injectable blood thinner).
• Women who could potentially become pregnant must have a negative pregnancy test before starting treatment, and must use two forms of birth control (one highly effective, one barrier method) starting at least 28 days before treatment begins, and must agree to ongoing pregnancy testing throughout the trial.
• Men must agree to use a condom during any sexual contact with a woman who could become pregnant, even if they have had a vasectomy.

Who may not be able to join:

• People who are currently receiving other systemic treatments for multiple myeloma (some exceptions apply, such as steroids for specific complications, bone-strengthening medications, or certain procedures for fractures or spinal problems).
• People whose myeloma no longer responds to anti-CD38 treatments (considered refractory to those treatments), unless the above inclusion conditions regarding prior CD38 therapy are met.
• People who have plasma cell leukaemia (a related but more aggressive blood cancer).
• People who have POEMS syndrome (a rare condition involving nerve damage, organ enlargement, hormone problems, abnormal proteins, and skin changes).
• People who have amyloidosis (a condition where abnormal proteins build up in organs).
• People who have a chronic lung condition called COPD where a specific breathing test shows their lung function is significantly reduced (below 50% of expected normal).
• Women who are pregnant or breastfeeding.
• People with uncontrolled high blood pressure (systolic above 160 mmHg or diastolic above 100 mmHg) or uncontrolled diabetes.
• People with an active hepatitis B or hepatitis C infection.
• People who test positive for HIV within 4 weeks of enrolling.
• People who test positive for active hepatitis B virus in the blood (some exceptions apply for people with evidence of past vaccination or fully resolved infection — confirm with trial site).
• People who test positive for hepatitis C, unless the infection has been fully cleared following antiviral treatment for at least 12 weeks.
• People with serious heart problems, including severe heart failure symptoms, uncontrolled irregular heartbeat, a heart attack within the past 4 months, a specific abnormal heart rhythm reading on an ECG, poor heart pumping function (below 40%), or certain structural heart conditions.
• People with high blood pressure in the lungs (pulmonary hypertension).
• People with severe digestive system problems that would prevent them from properly absorbing tablets or capsules taken by mouth.
• People with uncontrolled ongoing illness, including active serious infections or mental health or social situations that would make it difficult to follow the trial requirements.
• People with significant nerve damage (grade 3 or above) that is causing pain at the time of enrolment.
• People who cannot take any of the required supporting medications, including antivirals or blood thinners.
• People who have had major surgery within 3 weeks before the first dose of study treatment.
• People who have previously been treated with the study drug iberdomide.
• Women who plan to become pregnant or donate eggs during the treatment period or during the required contraception period after treatment ends.
• Men who plan to father a child or donate sperm during the treatment period or during the required contraception period after treatment ends.
• People who do not have the capacity to make informed decisions about participating.

Important: Always verify eligibility with the trial site directly before applying.